Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 16/20 | 0.78 |
| ▸ | PLA2G10 | O15496 | 8/20 | 0.78 |
| ▸ | PLA2G2E | Q9NZK7 | 6/20 | 0.78 |
| ▸ | PLA2G1B | P04054 | 6/20 | 0.78 |
| ▸ | PLA2G2D | Q9UNK4 | 5/20 | 0.78 |
| ▸ | PLA2G5 | P39877 | 5/20 | 0.78 |
| ▸ | PLA2G2F | Q9BZM2 | 4/20 | 0.78 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.78 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.78 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.78 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.78 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5150404 | 0.93 | PLA2G2A (0.84) | PLA2G2APLA2G10PLA2G2EPLA2G1BPLA2G2D | |
| Varespladib Methyl SCHEMBL29378302 | 0.91 | PLA2G2A (0.83) | PLA2G2APLA2G10PLA2G2EPLA2G1BPLA2G2D | |
| Varespladib Methyl SCHEMBL25678 | 0.91 | PLA2G2A (0.83) | PLA2G2APLA2G10PLA2G2EPLA2G1BPLA2G2D | |
| SCHEMBL5710708 | 0.90 | PLA2G2A (0.82) | PLA2G2APLA2G10PLA2G2EPLA2G1BPLA2G2D | |
| SCHEMBL5710700 | 0.88 | PLA2G2A (0.82) | PLA2G2APLA2G10PLA2G2EPLA2G1BPLA2G2D | |
| Varespladib SCHEMBL29358982 | 0.88 | PLA2G2A (1.00) | PLA2G2APLA2G10PLA2G2EPLA2G1BPLA2G2D | |
| Varespladib SCHEMBL26726 | 0.88 | PLA2G2A (1.00) | PLA2G2APLA2G10PLA2G2EPLA2G1BPLA2G2D | |
| SCHEMBL5710684 | 0.88 | PLA2G2A (0.78) | PLA2G2APLA2G10PLA2G2EPLA2G1BPLA2G2D | |
| SCHEMBL5710591 | 0.87 | PLA2G2A (0.80) | PLA2G2APLA2G10PLA2G2EPLA2G1BPLA2G2D | |
| SCHEMBL5710565 | 0.87 | PLA2G2A (0.80) | PLA2G2APLA2G10PLA2G2EPLA2G1BPLA2G2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202963-B1 | SPLA2 INHIBITORS | LILLY CO ELI (US) | 2007-01-03 | — | — | EP | claimed |
| US-6635670-B2 | Such as N-(2-((3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4 -yl)oxy)acetyl)glycine; inflammatory diseases | ELI LILLY AND COMPANY | 2003-10-21 | — | — | US | claimed |
| US-20030153770-A1 | Novel sPLA2 inhibitors | LIN HO-SHEN (US) | 2003-08-14 | — | — | US | claimed |
| EP-1202963-A1 | SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-05-08 | — | — | EP | claimed |
| WO-2001005761-A1 | sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
| WO-2013067579-A1 | ADIPOSITY-MODULATING MOLECULES AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-05-16 | — | — | WO | disclosed |
| EP-1202963-B1 | SPLA2 INHIBITORS | LILLY CO ELI (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1202963-B1 | SPLA2 INHIBITORS | LILLY CO ELI (US) | 2007-01-03 | — | — | EP | disclosed |
| US-6706752-B1 | HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2 INHIBITORS FOR INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF INFLAMMATORY DISEASES SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-16 | — | — | US | disclosed |
| US-6635670-B2 | Such as N-(2-((3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4 -yl)oxy)acetyl)glycine; inflammatory diseases | ELI LILLY AND COMPANY | 2003-10-21 | — | — | US | disclosed |
| US-20030153770-A1 | Novel sPLA2 inhibitors | LIN HO-SHEN (US) | 2003-08-14 | — | — | US | disclosed |
| EP-1202963-A1 | SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001005761-A1 | sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153770-A1 | Novel sPLA2 inhibitors | PLA2G12A, PLA2G4A, PLAAT2 | PLA2G2A 17/4885PLA2G10 11/4885PLA2G2E 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.